Area of research
Immunology · Oncology
Research interest
Research interests include Immune Cell Function and Interaction, Immune cells in cancer, Cancer Immunotherapy and Biomarkers, and T-cell and B-cell Immunology.
Adaptive NK Cells Exhibit Tumor-Specific Immune Memory and Cytotoxicity in Ovarian Cancer
Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer
The extracellular matrix – immune microenvironment crosstalk in cancer therapy: Challenges and opportunities
FPR2 Shapes an Immune-Excluded Pancreatic Tumor Microenvironment and Drives T-cell Exhaustion in a Sex-Dependent Manner
Sex dimorphism in the tumor microenvironment – From bench to bedside and back
Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer
Targeting Myeloid Suppressive Cells Revives Cytotoxic Anti-Tumor Responses in Pancreatic Cancer
Selenium stimulates the antitumour immunity: Insights to future research
Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function
Distinct developmental pathways from blood monocytes generate human lung macrophage diversity
Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS
Independent control of natural killer cell responsiveness and homeostasis at steady-state by CD11c+ dendritic cells
Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity
Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity
Inhibiton of tumor-derived prostaglandin-e2 prevents the induction of human myeloid-derived suppressor cells (MDSCs) and rescues anti-tumor immunity
Doxorubicin sensitizes human tumor cells to NK cell‐ and T‐cell‐mediated killing by augmented TRAIL receptor signaling
HER2/HER3 Signaling Regulates NK Cell-Mediated Cytotoxicity via MHC Class I Chain-Related Molecule A and B Expression in Human Breast Cancer Cell Lines
Opposing consequences of signaling through EGF family members